Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:VIVO
- CUSIP: 58958410
- Web: www.meridianbioscience.com
Capitalization:- Market Cap: $576.07 million
- Outstanding Shares: 42,203,000
Average Prices:- 50 Day Moving Avg: $14.56
- 200 Day Moving Avg: $14.00
- 52 Week Range: $10.75 - $19.85
P/E:- Trailing P/E Ratio: 27.30
- Foreward P/E Ratio: 19.78
- P/E Growth: 1.19
Sales & Book Value:- Annual Revenue: $198.07 million
- Price / Sales: 2.91
- Book Value: $3.97 per share
- Price / Book: 3.44
Dividend:- Annual Dividend: $0.50
- Dividend Yield: 3.7%
Profitability:- EBIDTA: $52.8 million
- Net Margins: 10.77%
- Return on Equity: 16.93%
- Return on Assets: 11.36%
Debt:- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 6.47%
- Quick Ratio: 4.42%
Misc:- Average Volume: 259,111 shs.
- Beta: 0.89
- Short Ratio: 15.83
Frequently Asked Questions for Meridian Bioscience (NASDAQ:VIVO)
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience announced a quarterly dividend on Thursday, July 27th. Shareholders of record on Monday, August 7th will be paid a dividend of $0.125 per share on Thursday, August 17th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date of this dividend is Thursday, August 3rd. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience Inc. (NASDAQ:VIVO) posted its earnings results on Thursday, July, 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.16. The firm earned $50.14 million during the quarter, compared to the consensus estimate of $49.13 million. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.21 earnings per share. View Meridian Bioscience's Earnings History.
When will Meridian Bioscience make its next earnings announcement?
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $0.64-0.69 for the period, compared to the Thomson Reuters consensus estimate of $0.68. The company issued revenue guidance of $193-199 million, compared to the consensus revenue estimate of $197.58 million.
Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?
4 analysts have issued 12 month target prices for Meridian Bioscience's shares. Their forecasts range from $9.00 to $19.00. On average, they expect Meridian Bioscience's share price to reach $14.33 in the next twelve months. View Analyst Ratings for Meridian Bioscience.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Intersect ENT (XENT), Orthofix International N.V. (OFIX), AtriCure (ATRC), Cryolife (CRY), Landauer (LDR), Consort Medical plc (CSRT), STAAR Surgical Company (STAA), Antares Pharma (ATRS), Invacare Corporation (IVC), Exactech (EXAC), Utah Medical Products (UTMD), Sientra (SIEN), Ocular Therapeutix (OCUL), SeaSpine Holdings Corporation (SPNE) and T2 Biosystems (TTOO).
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- John A. Kraeutler, Chairman of the Board, President, Chief Executive Officer
- Lawrence J. Baldini, Executive Vice President and President, Global Operations
- Richard L. Eberly, Executive Vice President, President, Chief Commercial Officer
- Melissa A. Lueke, Chief Financial Officer, Executive Vice President, Secretary
- Marco G. Calzavara, President and Managing Director of Meridian Bioscience Europe
- Vecheslav A. Elagin Ph.D., Executive Vice President - Research and Development
- Susan D. Rolih, Executive Vice President - Regulatory & Quality Systems
- David C. Phillips, Lead Independent Director
- James M. Anderson, Independent Director
- Dwight E. Ellingwood, Independent Director
Who owns Meridian Bioscience stock?
Meridian Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Renaissance Technologies LLC (4.66%), Dimensional Fund Advisors LP (3.95%), State Street Corp (2.92%), New York State Common Retirement Fund (2.51%) and Prudential PLC (2.19%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?
Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC, BTIM Corp., Wells Fargo & Company MN, Citadel Advisors LLC, Schroder Investment Management Group, North Star Investment Management Corp., Systematic Financial Management LP and Nine Chapters Capital Management LLC. Company insiders that have sold Meridian Bioscience stock in the last year include Richard Eberly and Vecheslav A Elagin. View Insider Buying and Selling for Meridian Bioscience.
Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?
Meridian Bioscience's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Intrinsic Edge Capital Management LLC, Dimensional Fund Advisors LP, Prudential Financial Inc., GSA Capital Partners LLP, OxFORD Asset Management LLP, Balter Liquid Alternatives LLC and Parametric Portfolio Associates LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy Meridian Bioscience stock?
Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of Meridian Bioscience stock can currently be purchased for approximately $13.65.
MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Hold Ratings |
| Consensus Rating: | Hold (Score: 1.75) |
| Consensus Price Target: | $14.33 (5.01% upside) |
Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/3/2017 | Canaccord Genuity | Boost Price Target | Hold | $13.00 -> $15.00 | Low |  |
| 3/28/2017 | CL King | Initiated Coverage | Neutral -> Neutral | | High | |
| 1/31/2017 | Craig Hallum | Downgrade | Buy -> Hold | | N/A | |
| 1/25/2017 | Piper Jaffray Companies | Set Price Target | Sell | $9.00 | N/A | |
| 7/29/2016 | Hilliard Lyons | Downgrade | Buy -> Hold | | N/A | |
| 3/29/2016 | Robert W. Baird | Reiterated Rating | Hold | $20.00 | N/A | |
| 1/27/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Meridian Bioscience (NASDAQ:VIVO)Earnings History by Quarter for Meridian Bioscience (NASDAQ VIVO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | $0.15 | | | | | N/A | |
| 7/27/2017 | Q3 2017 | $0.16 | $0.16 | $49.13 million | $50.14 million | View | N/A | |
| 4/28/2017 | Q2 2017 | $0.19 | $0.22 | $51.16 million | $54.13 million | View | N/A | |
| 1/25/2017 | Q1 2017 | $0.20 | $0.15 | $51.15 million | $46.80 million | View | N/A | |
| 11/10/2016 | Q4 2016 | $0.14 | $0.14 | $47.17 million | $47.00 million | View | N/A | |
| 7/28/2016 | Q3 | $0.22 | $0.21 | $52.85 million | $50.70 million | View | N/A | |
| 4/28/2016 | Q2 | $0.24 | $0.24 | $52.10 million | $51.30 million | View | N/A | |
| 1/27/2016 | Q1 | $0.21 | $0.21 | $48.60 million | $47.20 million | View | N/A | |
| 11/5/2015 | Q4 | $0.21 | $0.20 | $45.70 million | $47.10 million | View | N/A | |
| 7/23/2015 | Q3 | $0.22 | $0.22 | $48.60 million | $48.20 million | View | N/A | |
| 4/23/2015 | Q115 | $0.24 | $0.24 | $50.50 million | $51.55 million | View | N/A | |
| 1/22/2015 | Q414 | $0.19 | $0.19 | $46.20 million | $48.00 million | View | N/A | |
| 11/6/2014 | Q4 | $0.22 | $0.20 | $48.94 million | $46.70 million | View | N/A | |
| 7/24/2014 | Q3 | $0.22 | $0.21 | $47.96 million | $47.20 million | View | N/A | |
| 4/24/2014 | Q214 | $0.27 | $0.24 | $52.18 million | $50.13 million | View | N/A | |
| 1/22/2014 | Q114 | $0.18 | $0.18 | $47.59 million | $44.80 million | View | N/A | |
| 11/7/2013 | Q313 | $0.23 | $0.22 | $49.24 million | $48.96 million | View | N/A | |
| 7/25/2013 | Q3 2013 | $0.21 | $0.24 | $47.00 million | $47.10 million | View | N/A | |
| 4/25/2013 | Q2 2013 | $0.24 | $0.24 | $49.66 million | $47.26 million | View | N/A | |
| 1/23/2013 | Q1 2013 | $0.19 | $0.20 | $44.34 million | $45.40 million | View | N/A | |
| 11/8/2012 | Q412 | $0.19 | $0.21 | $43.22 million | $43.70 million | View | N/A | |
| 7/26/2012 | | $0.22 | $0.21 | | | View | N/A | |
| 4/26/2012 | | $0.21 | $0.23 | | | View | N/A | |
| 1/25/2012 | | $0.19 | $0.17 | | | View | N/A | |
| 11/10/2011 | | $0.19 | $0.18 | | | View | N/A | |
| 7/21/2011 | | $0.21 | $0.17 | | | View | N/A | |
| 4/21/2011 | | $0.20 | $0.20 | | | View | N/A | |
| 1/20/2011 | | $0.19 | $0.15 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)2017 EPS Consensus Estimate: $0.81
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.17 | $0.17 | $0.17 |
| Q2 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q3 2017 | 1 | $0.22 | $0.22 | $0.22 |
| Q4 2017 | 1 | $0.20 | $0.20 | $0.20 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)| Most Recent Dividend: | 8/17/2017 |
| Annual Dividend: | $0.50 |
| Dividend Yield: | 3.66% |
| Payout Ratio: | 98.04% (Trailing 12 Months of Earnings)
74.63% (Based on This Year's Estimates)
72.46% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Meridian Bioscience (NASDAQ VIVO)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/27/2017 | Quarterly | $0.13 | 3.55% | 8/3/2017 | 8/7/2017 | 8/17/2017 |
| 4/27/2017 | quarterly | $0.13 | 3.33% | 5/4/2017 | 5/8/2017 | 5/18/2017 |
| 1/25/2017 | quarterly | $0.13 | 3.91% | 2/2/2017 | 2/6/2017 | 2/16/2017 |
| 11/10/2016 | Quarterly | $0.20 | 4.6% | 11/17/2016 | 11/21/2016 | 12/1/2016 |
| 7/28/2016 | quarterly | $0.20 | 4.13% | 8/4/2016 | 8/8/2016 | 8/18/2016 |
| 4/28/2016 | quarterly | $0.20 | 4.19% | 5/5/2016 | 5/9/2016 | 5/19/2016 |
| 1/27/2016 | quarterly | $0.20 | 4.29% | 2/4/2016 | 2/8/2016 | 2/18/2016 |
| 11/5/2015 | quarterly | $0.20 | 3.89% | 11/12/2015 | 11/16/2015 | 11/27/2015 |
| 7/23/2015 | quarterly | $0.20 | 4.28% | 7/30/2015 | 8/3/2015 | 8/13/2015 |
| 4/23/2015 | quarterly | $0.20 | 4.18% | 4/30/2015 | 5/4/2015 | 5/14/2015 |
| 1/22/2015 | quarterly | $0.20 | 4.51% | 1/29/2015 | 2/2/2015 | 2/13/2015 |
| 11/6/2014 | quarterly | $0.20 | 4.75% | 11/13/2014 | 11/17/2014 | 11/28/2014 |
| 7/24/2014 | quarterly | $0.20 | 3.99% | 7/31/2014 | 8/4/2014 | 8/14/2014 |
| 4/24/2014 | quarterly | $0.20 | 4.05% | 5/1/2014 | 5/5/2014 | 5/15/2014 |
| 1/22/2014 | quarterly | $0.20 | 3.13% | 1/30/2014 | 2/3/2014 | 2/14/2014 |
| 11/7/2013 | quarterly | $0.19 | 3.04% | 11/14/2013 | 11/18/2013 | 11/29/2013 |
| 7/25/2013 | quarterly | $0.19 | 3.13% | 8/1/2013 | 8/5/2013 | 8/15/2013 |
| 4/25/2013 | quarterly | $0.19 | 3.88% | 5/1/2013 | 5/4/2013 | 5/14/2013 |
| 12/4/2012 | quarterly | $0.19 | | | 12/14/2012 | 12/24/2012 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Meridian Bioscience (NASDAQ:VIVO)Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 86.50%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/2/2017 | Melissa Lueke | CFO | Buy | 4,000 | $12.59 | $50,360.00 | |
| 1/26/2017 | Lawrence Baldini | EVP | Buy | 4,000 | $12.70 | $50,800.00 | |
| 12/2/2016 | Vecheslav A Elagin | EVP | Sell | 7,883 | $17.30 | $136,375.90 | |
| 11/30/2016 | Dwight E Ellingwood | Director | Buy | 1,020 | $17.12 | $17,462.40 | |
| 11/16/2016 | Richard Eberly | EVP | Sell | 4,926 | $17.00 | $83,742.00 | |
| 11/4/2016 | John A Kraeutler | Chairman | Buy | 5,000 | $16.13 | $80,650.00 | |
| 11/3/2016 | Lawrence Baldini | EVP | Buy | 4,900 | $16.00 | $78,400.00 | |
| 8/11/2016 | John Mcilwraith | Director | Buy | 1,000 | $19.57 | $19,570.00 | |
| 4/29/2016 | Catherine Sazdanoff | Director | Buy | 7,700 | $19.20 | $147,840.00 | |
| 12/9/2015 | Vecheslav A Elagin | EVP | Sell | 7,500 | $19.75 | $148,125.00 | |
| 12/1/2015 | Richard Eberly | EVP | Sell | 4,934 | $19.61 | $96,755.74 | |
| 3/2/2015 | Marviette D Johnson | VP | Sell | 1,917 | $19.91 | $38,167.47 | |
| 1/23/2015 | Dwight E Ellingwood | Director | Buy | 1,980 | $17.74 | $35,125.20 | |
| 12/1/2014 | Susan Rolih | EVP | Sell | 11,219 | $16.46 | $184,664.74 | |
| 11/21/2014 | Dwight E Ellingwood | Director | Buy | 1,000 | $16.08 | $16,080.00 | |
| 11/18/2014 | John A Kraeutler | CEO | Sell | 10,500 | $16.20 | $170,100.00 | |
| 11/18/2014 | Melissa Lueke | CFO | Sell | 6,713 | $16.20 | $108,750.60 | |
| 11/11/2014 | David Phillips | Director | Buy | 10,000 | $16.89 | $168,900.00 | |
| 6/13/2014 | Robert J Ready | Director | Sell | 2,700 | $20.03 | $54,081.00 | |
| 12/5/2013 | Vecheslav Elagin | EVP | Sell | 4,141 | $23.74 | $98,307.34 | |
| 11/22/2013 | Susan Rolih | EVP | Sell | 9,086 | $24.18 | $219,699.48 | |
| 11/21/2013 | Richard Eberly | EVP | Sell | 4,926 | $24.50 | $120,687.00 | |
| 11/19/2013 | Lawrence Baldini | VP | Sell | 4,926 | $24.26 | $119,504.76 | |
| 11/11/2013 | John Kraeutler | CEO | Sell | 5,250 | $25.27 | $132,667.50 | |
| 7/26/2013 | Lawrence Baldini | VP | Sell | 32,000 | $24.14 | $772,480.00 | |
| 5/1/2013 | John A Kraeutler | CEO | Buy | 5,000 | $19.63 | $98,150.00 | |
| 12/3/2012 | Lawrence Baldini | VP | Sell | 32,500 | $20.00 | $650,000.00 | |
| 11/13/2012 | Robert J Ready | Director | Sell | 1,800 | $19.46 | $35,028.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Meridian Bioscience (NASDAQ:VIVO)
Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Meridian Bioscience Inc. (VIVO) Will Announce Quarterly Sales of $47.70 Million
www.americanbankingnews.com - August 16 at 3:42 AM |
| Brokerages Anticipate Meridian Bioscience Inc. (VIVO) Will Announce Earnings of $0.15 Per Share
www.americanbankingnews.com - August 14 at 4:26 PM |
| Head-To-Head Analysis: Meridian Bioscience (VIVO) and West Pharmaceutical Services (WST)
www.americanbankingnews.com - August 12 at 10:08 PM |
| Meridian Bioscience Inc. (VIVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 11 at 10:56 AM |
 | Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
www.zacks.com - August 10 at 9:27 AM |
 | Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test
finance.yahoo.com - August 10 at 9:27 AM |
| Meridian Bioscience Elects John Rice to the Board of Directors
finance.yahoo.com - August 9 at 8:55 AM |
| Meridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : August 8, 2017
finance.yahoo.com - August 9 at 8:55 AM |
| Bioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing
finance.yahoo.com - August 3 at 8:36 AM |
| Meridian Bioscience Inc. (VIVO) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - August 2 at 5:12 PM |
| Meridian Bioscience Inc. Plans Quarterly Dividend of $0.13 (NASDAQ:VIVO)
www.americanbankingnews.com - July 28 at 10:43 AM |
| Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : July 27, 2017
finance.yahoo.com - July 28 at 9:42 AM |
| Meridian Bioscience meets 3Q profit forecasts
finance.yahoo.com - July 28 at 9:42 AM |
| Meridian Bioscience Inc. (NASDAQ:VIVO) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - July 27 at 7:52 PM |
| Meridian Bioscience Inc. (NASDAQ:VIVO) Announces Quarterly Earnings Results
www.americanbankingnews.com - July 27 at 2:17 PM |
| Meridian Bioscience Inc. (NASDAQ:VIVO) Releases FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 10:07 AM |
 | Meridian Bioscience Q3 Profit Down 97%, Reiterates FY17 Outlook - Quick Facts
www.nasdaq.com - July 27 at 9:10 AM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Meridian Bioscience, Inc.
finance.yahoo.com - July 27 at 9:10 AM |
| Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge
finance.yahoo.com - July 27 at 9:10 AM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc. - VIVO
finance.yahoo.com - July 26 at 9:48 AM |
| Meridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China
finance.yahoo.com - July 21 at 8:26 AM |
| Meridian Bioscience Inc. (VIVO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 11:05 AM |
| FDA raises fresh concerns over Meridian's lead testing device
finance.yahoo.com - July 14 at 9:45 AM |
| Meridian Bioscience Comments on Recent FDA Press Statement
finance.yahoo.com - July 14 at 9:45 AM |
| FDA raises concerns about Meridian's plant that makes lead tests
finance.yahoo.com - July 14 at 9:45 AM |
| VIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Concerning Possible Securities Violations by Meridian Bioscience, Inc.
finance.yahoo.com - July 14 at 9:45 AM |
| MERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Meridian Bioscience, Inc. To Contact The Firm
finance.yahoo.com - July 14 at 9:45 AM |
| Zacks Investment Research Lowers Meridian Bioscience Inc. (VIVO) to Sell
www.americanbankingnews.com - July 13 at 8:50 AM |
| Head to Head Contrast: Hill-Rom Holdings (HRC) & Meridian Bioscience (VIVO)
www.americanbankingnews.com - July 12 at 7:47 AM |
| BidaskClub Downgrades Meridian Bioscience Inc. (VIVO) to Hold
www.americanbankingnews.com - July 6 at 3:20 PM |
| Zacks: Analysts Expect Meridian Bioscience Inc. (VIVO) Will Announce Quarterly Sales of $49.41 Million
www.americanbankingnews.com - July 5 at 11:47 AM |
| Zacks: Brokerages Anticipate Meridian Bioscience Inc. (NASDAQ:VIVO) Will Post Earnings of $0.16 Per Share
www.americanbankingnews.com - July 3 at 9:18 AM |
| Meridian Bioscience Inc. (VIVO) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 2 at 4:24 PM |
 | Meridian Bioscience (VIVO) Publishes Clarifying Comments in Response to U.S. Senators, FDA & CDC Regarding FDA Safety Notification Request
www.streetinsider.com - July 1 at 8:50 AM |
| Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics
finance.yahoo.com - July 1 at 8:50 AM |
 | Meridian Bioscience updates on FDA inpsection of Magellan
seekingalpha.com - June 30 at 1:59 PM |
| Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday
www.nasdaq.com - June 29 at 7:51 AM |
| Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal 2017 Operating Results on Thursday, July 27, 2017
finance.yahoo.com - June 29 at 7:51 AM |
| Meridian Bioscience Inc. (VIVO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 20 at 9:21 AM |
| Meridian Bioscience Inc. (VIVO) Short Interest Up 1.3% in May
www.americanbankingnews.com - June 15 at 4:26 PM |
| Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $49.41 Million
www.americanbankingnews.com - June 9 at 3:44 PM |
| Meridian Bioscience (VIVO) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 3:40 PM |
| Head to Head Contrast: Quidel (QDEL) vs. Meridian Bioscience (VIVO)
www.americanbankingnews.com - June 8 at 7:54 AM |
| VIVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Announces an Investigation Concerning Possible Securities Violations by Meridian Bioscience, Inc.
finance.yahoo.com - June 8 at 1:50 AM |
| IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Meridian Bioscience, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - June 8 at 1:50 AM |
| Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.16 EPS
www.americanbankingnews.com - June 7 at 7:50 AM |
 | INVESTOR ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Meridian ...
www.businesswire.com - June 7 at 12:45 AM |
| Meridian Bioscience (VIVO) Ways It's Working Closely with FDA Following Posting Related to Magellan Diagnostics
www.streetinsider.com - June 7 at 12:45 AM |
| INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Meridian Bioscience, Inc.
finance.yahoo.com - June 7 at 12:44 AM |
| Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics
finance.yahoo.com - June 7 at 12:44 AM |
Meridian Bioscience (VIVO) Chart for Sunday, August, 20, 2017
